Drugs / GT-220F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06866795 | Jul → Dec 2025 overdue | castration-resistant prostate carcinoma | Geode Therapeutics Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT-220F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06866795 ↗ |